Evidence map›Paper›PMID 36237330›Full record

ArticleFrontiers in oncology2022

Chromosome 11q loss and

Kaylee M Keller, Thomas F Eleveld, Linda Schild, Kim van den Handel, Marlinde van den Boogaard, Vicky Amo-Addae, Selma Eising, Kimberley Ober, Bianca Koopmans, Leendert Looijenga and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Kaylee M KellerDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Thomas F EleveldDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Linda SchildDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Kim van den HandelDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Marlinde van den BoogaardDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Vicky Amo-AddaeDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Selma EisingDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Kimberley OberDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Bianca KoopmansDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Leendert LooijengaDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Godelieve A M TytgatDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Bauke YlstraDepartment of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Jan J MolenaarDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
M Emmy M DolmanDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Sander R van HooffDepartment of Research, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Princess Máxima Center · NLAmsterdam University Medical Centers · NLUNSW Sydney · AUUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is the most common extracranial solid tumor found in children and despite intense multi-modal therapeutic approaches, low overall survival rates of high-risk patients persist. Tumors with heterozygous loss of chromosome 11q and

Indexed as

checkpoint kinase 1 (CHK1)chromosome 11q deletionMYCN amplificationneuroblastomapediatric cancerprexasertibreplication stresssynergy

Identifiers

PMID36237330
PMCPMC9552537
OpenAlexW4297381384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.